TVTX · ISSUER CIK 1438533
Travere Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 9 Travere Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $80.1M of sales on SEC Form 4.
↗9 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 10 of 11 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$80.1MInsider selling
−$80.1MNet open-market
Oct 19, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 202616:05 | Oct 15, 2026 | TVTX | CHIEF EXECUTIVE OFFICER, Director | S · Sell10b5-1 | $53.82 | −243,735 | 432,886 | -36% | −$13.1M | ||
| Oct 19, 202616:05 | Oct 15, 2026 | TVTX | CHIEF EXECUTIVE OFFICER, Director | M · Exercise10b5-1 | $12.15 | +243,735 | 676,621 | +56% | $3.0M | ||
| Sep 17, 202621:35 | Sep 16, 2026from Sep 15, 2026 | TVTX | Chief Research Officer | S · Sell10b5-1 | $62.83 | −209,048 | 98,197 | -68% | −$13.1M | ||
| Sep 17, 202621:35 | Sep 16, 2026from Sep 15, 2026 | TVTX | Chief Research Officer | M · Exercise10b5-1 | $21.41 | +191,500 | 211,047 | +980% | $4.1M | ||
| Sep 17, 202621:35 | Sep 17, 2026from Sep 15, 2026 | TVTX | EVP, CHIEF COMMERCIAL OFFICER | S · Sell10b5-1 | $63.06 | −283,189 | 117,066 | -71% | −$17.9M | ||
| Sep 17, 202621:35 | Sep 17, 2026from Sep 15, 2026 | TVTX | EVP, CHIEF COMMERCIAL OFFICER | M · Exercise10b5-1 | $15.69 | +258,189 | 125,348 | — | $4.1M | ||
| Sep 17, 202621:33 | Sep 15, 2026 | TVTX | EVP, Head of R&D & CMO | S · Sell10b5-1 | $62.34 | −44,674 | 100,491 | -31% | −$2.8M | ||
| Sep 17, 202621:33 | Sep 15, 2026 | TVTX | EVP, Head of R&D & CMO | M · Exercise10b5-1 | $8.93 | +32,395 | 145,165 | +29% | $289K | ||
| Sep 17, 202621:32 | Sep 15, 2026 | TVTX | Chief Legal Officer and GC | S · Sell10b5-1 | $62.34 | −37,500 | 105,389 | -26% | −$2.3M | ||
| Sep 17, 202621:32 | Sep 15, 2026 | TVTX | Chief Legal Officer and GC | M · Exercise10b5-1 | $15.46 | +37,500 | 142,889 | +36% | $580K | ||
| Sep 17, 202621:31 | Sep 17, 2026from Sep 15, 2026 | TVTX | CHIEF EXECUTIVE OFFICER, Director | S · Sell10b5-1 | $63.48 | −400,000 | 432,886 | -48% | −$25.4M | ||
| Sep 17, 202621:31 | Sep 17, 2026from Sep 15, 2026 | TVTX | CHIEF EXECUTIVE OFFICER, Director | M · Exercise10b5-1 | $23.34 | +400,000 | 541,379 | +283% | $9.3M | ||
| Sep 17, 202621:30 | Sep 15, 2026 | TVTX | CHIEF FINANCIAL OFFICER | S · Sell10b5-1 | $62.34 | −50,508 | 87,508 | -37% | −$3.1M | ||
| Sep 17, 202621:30 | Sep 15, 2026 | TVTX | CHIEF FINANCIAL OFFICER | M · Exercise10b5-1 | $17.44 | +20,000 | 138,016 | +17% | $349K | ||
| Sep 17, 202621:29 | Sep 15, 2026 | TVTX | SVP, CHIEF ACCOUNTING OFFICER | S · Sell10b5-1 | $62.33 | −5,375 | 42,353 | -11% | −$335K | ||
| Sep 17, 202621:29 | Sep 15, 2026 | TVTX | SVP, CHIEF ACCOUNTING OFFICER | M · Exercise10b5-1 | $24.19 | +5,375 | 47,728 | +13% | $130K | ||
| Sep 11, 202616:05 | Sep 10, 2026 | TVTX | Director | S · Sell10b5-1 | $67.31 | −20,000 | 91,500 | -18% | −$1.3M | ||
| Sep 11, 202616:05 | Sep 10, 2026 | TVTX | Director | M · Exercise10b5-1 | $21.98 | +20,000 | 111,500 | +22% | $440K | ||
| Sep 3, 202616:05 | Sep 2, 2026 | TVTX | CHIEF FINANCIAL OFFICER | S · Sell | $66.37 | −642 | 118,016 | -1% | −$43K | ||
| Aug 19, 202616:05 | Aug 18, 2026from Aug 17, 2026 | TVTX | Director | S · Sell10b5-1 | $63.28 | −10,000 | 61,500 | -14% | −$633K | ||
| Aug 19, 202616:05 | Aug 18, 2026from Aug 17, 2026 | TVTX | Director | M · Exercise10b5-1 | $17.44 | +10,000 | 66,500 | +18% | $174K |